The cumulative relapse rate and the cumulative non-relapse rate in both group also have no statistical difference [(10.87.2)% versus (20.010.7)% ( em P /em =0.957) and (23.912.4)% versus (7.16.9)% ( em P /em =0.224), respectively]. Conclusion The efficacy of Ph+ALL treated with combination of chemotherapy and TKIs and followed by allo-HSCT is comparable to that of Ph?ALL with allo-HSCT. strong class=”kwd-title” Keywords: Ph chromosome, Leukemia, Cd248 lymphoblastic, acute, Tyrosine kinase inhibitor, Hematopoietic stem cell transplantation, allogeneic, Case control study PhPh+ALLALL2%~7ALL20%~40%[1]C[2]Ph+ALLallo-HSCTDFSTKIPh+ALLTKIallo-HSCTPh+ALLTKIallo-HSCTPh+ALLPh+ALLOSPh?ALLallo-HSCTOS 12003120148allo-HSCT55BB-ALL55Ph+ALL 211TKI1TKI19TKI19Ph+ALL34Ph?ALL 2ALLMICM[3]Wright-GiemsaPOXPASCD34HLA-DRCD10CD19CD20CD22CyCD79aCyCD3CD4CD5CD7CD8CD13CD14CD15CD33CD117cMPOGRT-PCR41BCR-ABL190/210 3TKIVDCP[Cy]MTXMAE[Ara-C]Ph+ALL400~600 mg/d1263.2%100 mg/d (736.8%1)TKI10914~146d 3947.4%31052.6%100 d+100 dTKI400 mg/d100 mg/d1[19TKI27 d~1221] 4Bu/CyTBI/CyBuFluBu/CyAra-C 2 gm?2 d?1?11~?9 dBu 4 mg kg?1 d?13.2 mg kg?1 d?1?8~?6 d; Cy 1.8 gm?2d?1?5~?4 dTBI/CyAra-C 2 gm?2d?1?10~?8 dTBI 5 Gy1?7~?6 d; Cy 1.8 gm?2d?1?5~?4 dBu/FluAra-C 2 gm?2d?1?10~?8 dBu 4 mg kg?1 d?13.2 mg kg?1 d?1?6~?4 dFlu200 mg/m250 mg/d500 mg/m21 d250 mg/m22 d250 mg/m21 dHLAATG7.5~10 mg/kg3~4 d 5GVHDCsAMTXMMFGVHDCsACsACsA150~250 ng/L3MMF 7.5 mg/kg21MTX 15 mg/m21 d10 mg/m23+5+11 d 6GVHDGVHD(aGVHD)[4]GVHD(cGVHD)NIH[5] 7ALLallo-HSCT[6]HLACD34+TKIallo-HSCT19Ph+ALL19Ph?ALLallo-HSCT201412 8Kaplan-MeierOSaGVHDcGVHDNRMMann-Whitney em P /em 0.05SPSS 16.0 ALLallo-HSCTPh+ALLPh?ALLWBC30109/LHLAMNCCD34+1 1 Ph+ALLPh?ALL thead Ph+ALL(19Ph?ALL19 em P /em /thead [()]1.000?10(52.6)9(47.4)?9(47.4)10(52.6)38(7~49)30(5~59)0.056WBC[()]0.305?30109/L9(50)5(27.8)? 30109/L9(50)13(72.2)CNSL[()]1.000?2(10.5)3(15.8)?17(89.5)16(84.2)[()]0.890?CR116(84.2)15(78.9)?CR22(10.5)3(15.8)?CR31(5.3)1(5.3)[()]0.830?BM+PB15(78.9)16(84.2)?PB2(10.5)1(5.3)?PB2(10.5)2(10.5)HLA[()]1.000?9(47.4)8(42.1)?10(52.6)11(57.9)[()]0.325?2013201410(52.6)6(31.6)?20139(47.4)13(68.4)[()]0.324?Bu/Cy11(57.9)13(68.4)?TBI/Cy8(42.1)5(26.3)?Bu/Flu0(0)1(5.3)(108/kg)12.726.2812.884.820.931CD34+(109/kg)4.492.913.952.870.578 Open in a separate window CRBMPBBuCyTBIFluCNSL Ph+ALL19Ph?ALL34Ph?ALL3OS74.311.467.88.6% em P /em =0.520Ph+ALL19Ph?ALLPh?ALLPh+ALLPh?ALLOSDFS 11FISHDNADNA-STRPh+ALLPh?ALL12(9~23) d1310~20) d em P /em =0.28414(10~91) d17(10~120) d em P /em =0.246) em P /em 0.05 2OSDFSPh+Ph?ALL13(3~59)34(5~102) em P /em =0.037Ph+ALLPh?ALL3OS67.512.474.311.4% em P /em =0.4343DFS67.812.474.311.4% em P /em =0.456 Ezutromid 3GVHDPh+ALLPh?ALL~aGVHD15.88.421.19.4% em P /em =0.665~aGVHD5.65.411.57.6% em P /em =0.541cGVHD44.114.044.113.0% em P /em =0.835cGVHD13.18.76.26.1% em P /em =0.379 4RRNRMPh+ALLPh?ALLRR10.87.2%20.010.7% em P /em =0.957NRM23.912.47.16.9% em P /em =0.224Ph+ALL322Ph?ALL31 Ph+ALLB-ALLPh+ALL60%~80%Ph?ALL[7]Ph+ALLPh?ALL5OS19%[8]45%[9]allo-HSCTPh+ALL5[8]TKIPh+ALLTKI90%[10]Ph+ALL5OS5938% em Ezutromid P /em 0.001[11]TKIallo-HSCTPh+ALLTKIPh+ALLallo-HSCTallo-HSCT[12]C[13]Ph+ALLTKIallo-HSCTPh?ALLallo-HSCT3OSDFSTKIallo-HSCTPhPh+ALLPh?ALL TKIPh+ALLPh+ALLMRDMRDPh+ALLTKITKITKIPh+ALL TKITKIBCR-ABLSrc325ABL[14][15]Ph+ALL192 Ph+ALLPh?ALLallo-HSCTTKIPh+ALLPh+ALLTKIallo-HSCTPh?ALLallo-HSCT Funding Statement 8137066781200358201202017. and number of infused mononuclear cells and CD34+ cells were comparable between two groups of Ph+ and 19 Ph?ALL patients. The median time of engraftment of neutrophil cells was 12 days versus 13 days ( em P /em =0.284) and that of platelet 14 days versus 17 days Ezutromid ( em P /em =0.246), which were comparable between two groups. The estimated 3-year overall survival (OS) in Ph+ and Ph-ALL groups was (67.512.4)% versus (74.311.4)% ( em P /em =0.434) and 3-year disease free survival (DFS) was (67.812.4)% versus (74.311.4)% ( em P /em =0.456), respectively. The cumulative incidence of degree – acute graft-versus-host disease (aGVHD) in Ph+ and Ph?ALL group was (15.88.4)% versus (21.19.4)% ( em P /em =0.665) and that of degree – aGVHD was (5.65.4)% versus (11.57.6)% ( em P /em =0.541), respectively. The cumulative incidence of cGVHD was (44.114.0)% in Ph+ALL group versus (44.113.0)% in Ezutromid Ph?ALL group ( em P /em =0.835) and that of extensive cGVHD was (13.18.7)% versus (6.26.1)% ( em P /em =0.379), respectively. The cumulative relapse rate and the cumulative non-relapse rate in both group also have no statistical difference [(10.87.2)% versus (20.010.7)% ( em P /em =0.957) and (23.912.4)% versus (7.16.9)% ( em P /em =0.224), respectively]. Conclusion The efficacy of Ph+ALL treated with combination of chemotherapy and TKIs and followed by allo-HSCT is comparable to that of Ph?ALL with allo-HSCT. strong class=”kwd-title” Keywords: Ph chromosome, Leukemia, lymphoblastic, acute, Tyrosine kinase inhibitor, Hematopoietic stem cell transplantation, allogeneic, Case control study PhPh+ALLALL2%~7ALL20%~40%[1]C[2]Ph+ALLallo-HSCTDFSTKIPh+ALLTKIallo-HSCTPh+ALLTKIallo-HSCTPh+ALLPh+ALLOSPh?ALLallo-HSCTOS 12003120148allo-HSCT55BB-ALL55Ph+ALL 211TKI1TKI19TKI19Ph+ALL34Ph?ALL 2ALLMICM[3]Wright-GiemsaPOXPASCD34HLA-DRCD10CD19CD20CD22CyCD79aCyCD3CD4CD5CD7CD8CD13CD14CD15CD33CD117cMPOGRT-PCR41BCR-ABL190/210 3TKIVDCP[Cy]MTXMAE[Ara-C]Ph+ALL400~600 mg/d1263.2%100 mg/d (736.8%1)TKI10914~146d 3947.4%31052.6%100 d+100 dTKI400 mg/d100 mg/d1[19TKI27 d~1221] 4Bu/CyTBI/CyBuFluBu/CyAra-C 2 gm?2 d?1?11~?9 dBu 4 mg kg?1 d?13.2 mg kg?1 d?1?8~?6 d; Cy 1.8 gm?2d?1?5~?4 dTBI/CyAra-C 2 gm?2d?1?10~?8 dTBI 5 Gy1?7~?6 d; Cy 1.8 gm?2d?1?5~?4 dBu/FluAra-C 2 gm?2d?1?10~?8 dBu 4 mg kg?1 d?13.2 mg kg?1 d?1?6~?4 dFlu200 mg/m250 mg/d500 mg/m21 d250 mg/m22 d250 mg/m21 dHLAATG7.5~10 mg/kg3~4 d 5GVHDCsAMTXMMFGVHDCsACsACsA150~250 ng/L3MMF 7.5 mg/kg21MTX 15 mg/m21 d10 mg/m23+5+11 d 6GVHDGVHD(aGVHD)[4]GVHD(cGVHD)NIH[5] 7ALLallo-HSCT[6]HLACD34+TKIallo-HSCT19Ph+ALL19Ph?ALLallo-HSCT201412 8Kaplan-MeierOSaGVHDcGVHDNRMMann-Whitney em P /em 0.05SPSS 16.0 ALLallo-HSCTPh+ALLPh?ALLWBC30109/LHLAMNCCD34+1 1 Ph+ALLPh?ALL thead Ph+ALL(19Ph?ALL19 em P /em /thead [()]1.000?10(52.6)9(47.4)?9(47.4)10(52.6)38(7~49)30(5~59)0.056WBC[()]0.305?30109/L9(50)5(27.8)? 30109/L9(50)13(72.2)CNSL[()]1.000?2(10.5)3(15.8)?17(89.5)16(84.2)[()]0.890?CR116(84.2)15(78.9)?CR22(10.5)3(15.8)?CR31(5.3)1(5.3)[()]0.830?BM+PB15(78.9)16(84.2)?PB2(10.5)1(5.3)?PB2(10.5)2(10.5)HLA[()]1.000?9(47.4)8(42.1)?10(52.6)11(57.9)[()]0.325?2013201410(52.6)6(31.6)?20139(47.4)13(68.4)[()]0.324?Bu/Cy11(57.9)13(68.4)?TBI/Cy8(42.1)5(26.3)?Bu/Flu0(0)1(5.3)(108/kg)12.726.2812.884.820.931CD34+(109/kg)4.492.913.952.870.578 Open in a separate window CRBMPBBuCyTBIFluCNSL Ph+ALL19Ph?ALL34Ph?ALL3OS74.311.467.88.6% em P /em =0.520Ph+ALL19Ph?ALLPh?ALLPh+ALLPh?ALLOSDFS 11FISHDNADNA-STRPh+ALLPh?ALL12(9~23) d1310~20) d em P /em =0.28414(10~91) d17(10~120) d em P /em =0.246) em P /em 0.05 2OSDFSPh+Ph?ALL13(3~59)34(5~102) em P /em =0.037Ph+ALLPh?ALL3OS67.512.474.311.4% em P /em =0.4343DFS67.812.474.311.4% em P /em =0.456 3GVHDPh+ALLPh?ALL~aGVHD15.88.421.19.4% em P /em =0.665~aGVHD5.65.411.57.6% em P /em =0.541cGVHD44.114.044.113.0% em P /em =0.835cGVHD13.18.76.26.1% em P /em =0.379 4RRNRMPh+ALLPh?ALLRR10.87.2%20.010.7% em P /em =0.957NRM23.912.47.16.9% em P /em =0.224Ph+ALL322Ph?ALL31 Ph+ALLB-ALLPh+ALL60%~80%Ph?ALL[7]Ph+ALLPh?ALL5OS19%[8]45%[9]allo-HSCTPh+ALL5[8]TKIPh+ALLTKI90%[10]Ph+ALL5OS5938% em P /em 0.001[11]TKIallo-HSCTPh+ALLTKIPh+ALLallo-HSCTallo-HSCT[12]C[13]Ph+ALLTKIallo-HSCTPh?ALLallo-HSCT3OSDFSTKIallo-HSCTPhPh+ALLPh?ALL TKIPh+ALLPh+ALLMRDMRDPh+ALLTKITKITKIPh+ALL TKITKIBCR-ABLSrc325ABL[14][15]Ph+ALL192 Ph+ALLPh?ALLallo-HSCTTKIPh+ALLPh+ALLTKIallo-HSCTPh?ALLallo-HSCT Funding Statement 8137066781200358201202017.